News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Analyst action
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This article provides an overview of Cognition Therapeutics Inc (CGTX) stock information, including its current price, market capitalization, and a note that more news is coming soon. It highlights where to find news, earnings, analyst ratings, and key developments for the company.
This Yahoo Finance page provides comprehensive information on Cognition Therapeutics, Inc. (CGTX), including its current stock price, historical data, company overview, financial performance, and analyst ratings. CGTX is a clinical-stage biopharmaceutical company developing therapeutics for age-related degenerative diseases, with its lead candidate zervimesine in …
Cognition Therapeutics (NASDAQ:CGTX) reported a quarterly loss of $0.04 per share, surpassing analysts' consensus estimate by $0.02. Following the earnings release, CGTX shares declined by $0.05 to $1.08. Institutional investors hold 43.35% of the stock, and analysts maintain a "Moderate Buy" consensus rating with …
Cognition Therapeutics Inc. reported a consolidated net loss of $3.9 million for Q2 2026, an improvement from a $6.7 million loss in Q2 2025, with diluted loss per share at $(0.04). The company had no product revenue and relied on grant funding, which totaled …
(RTTNews) - Cognition Therapeutics, Inc. (CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, reported second quarter results reflecting a narrowed net loss and provided a business update. The company's lead candidate, Zervimesine (CT1812), is an investigational once-daily oral therapy being evaluated …
Cognition Therapeutics reported its financial results for the second quarter of 2026, highlighting progress in its clinical and corporate priorities, particularly for its lead candidate zervimesine. The company held discussions with the FDA for a Phase 3 trial in dementia with Lewy bodies (DLB) …
Cognition Therapeutics (NASDAQ: CGTX) reported a Q2 2026 net loss of $3.9 million, a significant reduction from $6.7 million in Q2 2025. The company announced its intention to initiate a Phase 3 trial for zervimesine in dementia with Lewy bodies (DLB) psychosis in mid-2027 …
Cognition Therapeutics (CGTX) reported a Q2 loss of $0.04 per share, surpassing the Zacks Consensus Estimate of a $0.06 loss, marking a 33.33% surprise. However, the company missed revenue estimates, posting -$1 million against an expectation of zero revenue, and its shares have dropped …
The dementia-related psychosis market is anticipated to increase during the forecast period (2026–2036), owing to the rising burden of dementia, the emergence of novel therapies such as ACP-204 (Remlifanserin) (Acadia Pharmaceuticals), Xanomeline–trospium chloride (COBENFY) (Bristol Myers Squibb), Zervimesine (CT1812) (Cognition Therapeutics), and others, and …
Cognition Therapeutics, Inc. (NASDAQ:CGTX) has received a "Moderate Buy" consensus recommendation from analysts, with three issuing a buy rating and one a sell. The average 12-month price target is $3.33, while the company's shares recently traded at $0.92. Cognition Therapeutics, a clinical-stage biopharmaceutical company, …
This article provides details on the institutional confidence in Cognition Therapeutics Inc (CGTX), listing top institutional shareholders and their recent activity. Key investors like Bios Equity Partners, Davenport Asset Management, and BlackRock Institutional Trust Company are highlighted, along with changes in their shareholdings. The …
This article provides the quarterly and annual balance sheets for Cognition Therapeutics Inc (CGTX), offering detailed financial data for various assets, liabilities, and shareholder equity components. It also includes an FAQ section that defines key balance sheet metrics and answers specific questions about CGTX's …
This article provides a technical analysis of Cognition Therapeutics Inc (CGTX) stock, detailing its performance based on various indicators and moving averages. It highlights the current sell and neutral signals from indicators like MACD and RSI, and predominantly sell signals from moving averages. The …
This article provides the quarterly and annual income statements for Cognition Therapeutics Inc (CGTX), offering detailed financial data such as operating expenses, R&D expenses, operating profit, and net income. It allows for analysis of the company's financial performance and operational efficiency over various periods. …
Cognition Therapeutics Inc. (CGTX) is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related degenerative disorders of the central nervous system and retina. The company's lead candidate, zervimesine (CT1812), is in clinical programs for dementia with Lewy bodies (DLB) and Alzheimer’s …
Cognition Therapeutics (CGTX) announced its Q2 2024 earnings, highlighting progress in its Phase 2 trials for CT-1812 in Alzheimer's, dementia with Lewy bodies (DLB), and dry AMD. The company reported a 39% slowing of cognitive decline in its SHINE Alzheimer's trial and expects topline …
Cognition Therapeutics (NASDAQ:CGTX) is an early-stage company operating with a cash burn of US$20 million annually, with a cash runway of about 18 months based on its US$31 million cash reserves as of March 2026. While the company has reduced its cash burn by …
Search by ticker symbol or company name and select a result to open its chart.